Key Takeaway: Harrow reported its financial results for the second quarter of 2026, showcasing a significant revenue increase of 60% compared to the previous quarter and an 11% rise year-over-year. The company reaffirmed its full-year revenue guidance, projecting between $350 million and $365 million, alongside an Adjusted EBITDA forecast of $80 million to $100 million.
Market Sentiment Analysis
POSITIVE FACTORS
Quarterly revenue increased by 60% sequentially.
Year-over-year revenue growth of 11%.
Reiterated strong full-year financial guidance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
11.8%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
MELT-100
Phase 1 · Healthy Volunteers
Full Press Release Details
Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)
Frequently Asked Questions
What was Harrow's revenue for Q2 2026?
Harrow reported a revenue of $70.7 million for Q2 2026.
How much did Harrow's revenue increase sequentially?
The revenue increased by 60% sequentially.
What is Harrow's full-year revenue guidance for 2026?
Harrow's full-year revenue guidance is between $350 million and $365 million.
What is the projected Adjusted EBITDA for 2026?
The projected Adjusted EBITDA for 2026 is between $80 million and $100 million.